This article is more than 5 years old. Information may no longer be current.
Ocular Therapeutix advances sustained-release products through pipeline
Click Here to Manage Email Alerts
LAS VEGAS — Ocular Therapeutix is in the broad and late-stages of the pipelines for its anterior and posterior sustained-release therapies, according to a presentation here.
“Every year we have a lot of advances, a lot of status updates to show where we are,” Amar Sawhney, president and CEO of Ocular Therapeutix, said at a company media briefing at the American Academy of Ophthalmology annual meeting. “What we are hoping to accomplish is to transform eye care using sustained therapies.”
Amar Sawhney
Since the company’s 2014 milestones were announced at last year’s AAO meeting, the company has completed its phase 2b trial for OTX-TP (sustained-release travoprost) to treat glaucoma, its first phase 3 trial for Dextenza (OTX-DP; sustained-release dexamethasone) to treat allergic conjunctivitis and two phase 3 trials of Dextenza for the treatment of postoperative ocular pain. Ocular Therapeutix also showed the feasibility of its anti-VEGF drug depot for use in treating posterior eye diseases.
“This company has been very bright about identifying problems early as they occur in the life cycle of these products and solving those problems in a way that in many cases kills two birds with one stone and advances the product,” John A. Hovanesian, MD, said. “I think we’ll continue to see that kind of progress from this company that really understands this space of therapeutic use.”
Topline efficacy results for the phase 2 exploratory trial of Dextenza for the treatment of inflammatory dry eye are expected in the fourth quarter of 2015. The company also intends to conduct a second phase 3 trial for allergic conjunctivitis, finalize the clinical trial design for the first phase 3 OTX-TP trial and seek new drug application approval for Dextenza for postsurgical ocular pain, according to the presentation.
“Everything we will do will be the first of its kind. It’s a long journey, and we are extremely excited for the future,” Sawhney concluded. — by Kristie L. Kahl
Disclosure: Sawhney reports he is president and CEO of Ocular Therapeutix. Hovanesian reports he is a consultant, equity owner and speaker for Ocular Therapeutix.